信立泰主营业务为化学制药，专注于心血管、降血糖、抗肿瘤等治疗领域。公司总部位于深圳，是深成 500指数成分股之一。 截至2025年8月20日收盘，信立泰股价报50.24元，较前一交易日下跌0.57%。当日成交量为88055手，成 交金额达4.37亿元。 资金流向方面，8月20日主力资金净流出5236.49万元，近五日主力资金净流入3339.81万元。机构持股数 据显示，截至8月19日共有86家机构投资者持有公司股份，合计持股比例达74.71%。 风险提示：股市有风险，投资需谨慎。 公司最新披露的2025年半年度报告显示，上半年实现营业收入21.31亿元，同比增长4.32%；归属于上市 公司股东的净利润为3.65亿元，同比增长6.10%。报告期内研发投入达5.42亿元，占营收比重为 25.43%。新产品信超妥和复立安相继获批上市，在高血压治疗领域形成差异化产品组合。 ...

金融界2025年8月20日消息，工银前沿医疗股票A(001717) 最新净值3.4760元，下跌0.52%。该基金近1个 月收益率1.67%，同类排名964|1023；近6个月收益率30.63%，同类排名115|984；今年来收益率 32.12%，同类排名222|974。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 工银前沿医疗股票A股票持仓前十占比合计59.44%，分别为：恒瑞医药（9.51%）、科伦药业 （9.16%）、 ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，信立泰发布公告称，2025年半年度公司实现营业收入2，130，967，669.97 元，同比增长4.32%；归属于上市公司股东的净利润为365，078，698.05元，同比增长6.10%。 ...

Financial Performance - The company's total revenue is 2.131 billion yuan, with a net profit attributable to shareholders of 365 million yuan [1] - The net cash inflow from operating activities is 425 million yuan, which is a decrease of 108 million yuan compared to the same period last year, representing a year-on-year decline of 20.19% [1] Financial Ratios - The latest debt-to-asset ratio is 18.13%, an increase of 2.15 percentage points from the previous quarter [3] - The latest gross profit margin is 75.31%, a slight decrease of 0.01 percentage points from the previous quarter [3] - The latest return on equity (ROE) is 4.28%, down by 0.12 percentage points compared to the same period last year [3] Efficiency Metrics - The diluted earnings per share (EPS) is 0.33 yuan [4] - The latest total asset turnover ratio is 0.20 times, a decrease of 0.01 times compared to the same period last year, reflecting a year-on-year decline of 5.82% [4] - The latest inventory turnover ratio is 1.01 times, down by 0.22 times compared to the same period last year, indicating a year-on-year decline of 17.94% [4] Shareholder Structure - The number of shareholders is 24,000, with the top ten shareholders holding 772 million shares, accounting for 69.28% of the total share capital [4] - The largest shareholder is Xintai Pharmaceutical Co., Ltd., holding 56.99% of the shares [4]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has successfully promoted its products through external channels and accelerated its R&D progress [7] - The company has established a differentiated product portfolio in the hypertension field, enhancing its brand influence in chronic disease management [7] - The company is expected to achieve revenue of 44.54 billion, 53.44 billion, and 62.53 billion yuan, and net profit of 6.28 billion, 6.90 billion, and 7.96 billion yuan from 2025 to 2027, with corresponding PE ratios of 89.6, 81.6, and 70.8 [7] Financial Performance - In the first half of 2025, the company achieved revenue of 2.131 billion yuan, a year-on-year increase of 4.32%, and a net profit of 365 million yuan, a year-on-year increase of 6.10% [7] - The company’s R&D investment in the first half of 2025 was 542 million yuan, accounting for 25.43% of revenue [7] - The company’s revenue projections for 2025E, 2026E, and 2027E are 44.54 billion, 53.44 billion, and 62.53 billion yuan respectively, with net profit projections of 6.28 billion, 6.90 billion, and 7.96 billion yuan [6][7] Market Performance - The company’s stock performance over the last 12 months shows a range of fluctuations, with a maximum increase of 101% compared to the benchmark index [4]

Core Insights - The company reported a main revenue of 2.131 billion yuan for the first half of 2025, representing a year-on-year increase of 4.32% [1] - The net profit attributable to shareholders reached 365 million yuan, up 6.1% year-on-year [1] - The second quarter of 2025 saw a single-quarter main revenue of 1.069 billion yuan, reflecting a 12.3% year-on-year growth [1] Financial Performance - The net profit for the second quarter was 165 million yuan, marking a 14.55% increase compared to the same quarter last year [1] - The non-recurring net profit for the first half of 2025 was 347 million yuan, which is a 3.93% increase year-on-year [1] - The second quarter's non-recurring net profit was 155 million yuan, showing a 16.98% year-on-year growth [1][5] Profitability Metrics - The company's debt ratio stands at 18.13% [1] - Investment income amounted to 19.61 million yuan, while financial expenses were -8.79 million yuan [1] - The gross profit margin is reported at 75.31%, which is an increase of 5.88% year-on-year [8] Earnings Per Share - Earnings per share (EPS) for the company is 0.33 yuan, reflecting a year-on-year increase of 6.45% [8] - The operating cash flow per share is reported at 0.38 yuan, which is a decrease of 20.19% year-on-year [8] Shareholder Information - The largest shareholder is Xintai Pharmaceutical Co., Ltd., holding 57% of shares [12] - Other significant shareholders include China Industrial Bank and Shenzhen Xintai Pharmaceutical Co., Ltd. [12][13]

深圳信立泰药业股份有限公司 2025 年半年度报告全文 深圳信立泰药业股份有限公司 深圳信立泰药业股份有限公司 2025 年半年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人叶宇翔、主管会计工作负责人孔芸及会计机构负责人（会计 主管人员）孔芸声明：保证本半年度报告中财务报告的真实、准确、完整。 没有董事、监事、高级管理人员声明对年度报告内容的真实性、准确 性、完整性无法保证或存在异议。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因 素：可能存在研发失败、政策变化带来的价格下降、成本上升等风险。有关 风险因素及应对措施已在本报告"管理层讨论与分析"部分予以描述，敬请 投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 深圳信立泰药业股份 ...

Core Viewpoint - Shenzhen Salubris Pharmaceuticals Co., Ltd. reported a revenue increase of 4.32% year-on-year for the first half of 2025, indicating stable growth in its operations [1][2]. Financial Performance - The company's operating income for the reporting period was approximately CNY 2.13 billion, compared to CNY 2.04 billion in the same period last year, reflecting a growth of 4.32% [1]. - The net profit attributable to shareholders was approximately CNY 365.08 million, up 6.10% from CNY 344.09 million in the previous year [1]. - The net cash flow from operating activities decreased by 20.19%, amounting to approximately CNY 425.43 million, down from CNY 533.06 million [1]. - Basic and diluted earnings per share increased by 6.45% to CNY 0.33 [1]. - The weighted average return on equity slightly decreased to 4.19%, down from 4.29% [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately CNY 10.63 billion, an increase from CNY 10.47 billion at the end of the previous year [1]. - The net assets attributable to shareholders decreased by 1.99% to approximately CNY 8.54 billion [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,019 [2]. - The largest shareholder, Salubris Pharmaceuticals Co., Ltd., holds 56.99% of the shares [2][3]. - There were no changes in the controlling shareholder or actual controller during the reporting period [3].

该报告已经董事会审计委员会审议通过，董事会审议通过了上述报告。 （《深圳信立泰药业股份有限公司 2025 年半年度报告摘要》详见信息披露 媒体：《中国证券报》、《证券时报》和巨潮资讯网 www.cninfo.com.cn； 《深圳信立泰药业股份有限公司 2025 年半年度报告》、《深圳信立泰药业 股份有限公司 2025 年半年度财务报告》、《2025 年半年度非经营性资金占用及 其他关联资金往来情况汇总表》详见信息披露媒体：巨潮资讯网 www.cninfo.com.cn。） 证券代码：002294 证券简称：信立泰 编号：2025-041 深圳信立泰药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第六届董事会第十三次会议 于 2025 年 8 月 18 日上午 10 时，在公司会议室以现场、通讯及书面方式召开， 会议通知于 2025 年 8 月 7 日以电子邮件方式送达。应参加董事 9 人，实际参加 董事 9 人，其中，叶澄海、沈清、陈茜渝、王学恭以通讯方式出席会议，刘来平 以书面方式出席会议，出席董 ...

《深圳信立泰药业股份有限公司 2025 年半年度报告》、《深圳信立泰药业 股份有限公司 2025 年半年度财务报告》、《2025 年半年度非经营性资金占用及 其他关联资金往来情况汇总表》详见信息披露媒体：巨潮资讯网 www.cninfo.com.cn。） 证券代码：002294 证券简称：信立泰 编号：2025-042 深圳信立泰药业股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第六届监事会第十次会议于 通知于 2025 年 8 月 7 日以电子邮件方式送达。应参加监事 3 人，实际参加监事 席会议，会议由监事会主席李爱珍主持。本次会议召开符合法律法规和《公司章 程》等有关规定。 与会监事审议并形成如下决议： 一、 会议以 3 人同意，0 人反对，0 人弃权，审议通过了《深圳信立泰药业 股份有限公司 2025 年半年度报告》及报告摘要。 监事会认为，经审核，董事会编制和审议深圳信立泰药业股份有限公司 2025 年半年度报告的程序符合法律、行政法规和中国证监会及深圳证券交易所的规 定，报告内容真实、准确、 ...